









| 货号 | HS856016 |
|---|---|
| 品牌 | abinScience |
| 描述 |
Ixekizumab (HS856016) is a research-grade recombinant antibody targeting CTLA-8. Produced in mammalian cells with native-like glycosylation.
Highlights
|
| 种属反应性 | Human |
| 应用 | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| 同种型 | IgG4-kappa |
| 表达系统 | Mammalian cells |
| 经测试应用 | WB, FCM |
| 靶标 | CTLA-8, Cytotoxic T-lymphocyte-associated antigen 8, IL17, IL-17A, IL17A, CTLA8, IL-17, Interleukin-17A |
| 内毒素水平 | < 10 EU/mg |
| 纯度 | >95% purity as determined by SDS-PAGE. |
| 纯化方式 | Protein A/G purified from cell culture supernatant. |
| Accession号 | Q16552 |
| 状态 | Liquid |
| 保存溶液 | 0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA. |
| 稳定性和存储 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| 别名 | LY2439821, 1143503-69-8 |
| 背景 | Interleukin-17A (IL17A) is a ~17 kDa protein. Effector cytokine of innate and adaptive immune system involved in antimicrobial host defense and maintenance of tissue integrity. Signals via IL17RA-IL17RC heterodimeric receptor complex, triggering homotypic interaction of IL17RA and IL17RC chains with TRAF3IP2 adapter. This leads to downstream TRAF6-mediated activation of NF-kappa-B and MAPkinase pathways ultimately resulting in transcriptional activation of cytokines, chemokines, antimicrobial peptides and matrix metalloproteinases, with potential strong immune inflammation. Plays an important role in connecting T cell-mediated adaptive immunity and acute inflammatory response to destroy extracellular bacteria and fungi. As a signature effector cytokine of T-helper 17 cells (Th17), primarily induces neutrophil activation and recruitment at infection and inflammatory sites. IL17A is the therapeutic target of secukinumab (Cosentyx). 1. Boisson, B. et al. (2013) Immunity 39, 676-86. PMID: 24120361 2. Kuestner, RE. et al. (2007) Journal of immunology (Baltimore, Md. : 1950) 179, 5462-73. PMID: 17911633 3. Wright, JF. et al. (2008) Journal of immunology (Baltimore, Md. : 1950) 181, 2799-805. PMID: 18684971 4. Liu, C. et al. (2009) Science signaling 2, ra63. PMID: 19825828 5. Puel, A. et al. (2011) Science (New York, N.Y.) 332, 65-8. PMID: 21350122 6. Fossiez, F. et al. (1996) The Journal of experimental medicine 183, 2593-603. PMID: 8676080 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
| Isotype Control | Human IgG1 Recombinant Isotype Control Antibody (13R4) (HV080507) |

SEC-HPLC detection for Research Grade Ixekizumab.

Detects Human IL17A in indirect ELISAs.

Flow-cytometry using anti-human IL17A antibody. Jurkat cells were fixed and permeabilized, then stained with an irrelevant antibody (Blue Histogram) or an anti-human IL17A monoclonal antibody (Catalog HS856016, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, bound antibody was detected using Goat Anti-Human IgG H&L Polyclonal Antibody, FITC (abinScience: HF690414) and cells analysed on a NovoCyte Flow Cytometer.

SDS-PAGE for Research Grade Ixekizumab.

Western blot analysis was performed using anti-IL17A monoclonal antibody at 1μg/ml on various samples.
Lane 1: recombinant human IL17A (Catalog No: HS856011), 50ng
Lane 2: recombinant human IL17A (Catalog No: HS856011), 30ng
Lane 3: recombinant human IL17A (Catalog No: HS856011), 20ng
Lane 4: recombinant human IL17A (Catalog No: HS856011), 10ng











24小时产品查询

扫一扫关注我们

专属渠道经理